Estrogen receptor-beta variants are associated with increased risk of Alzheimer's disease in women with Down syndrome

25Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background/Aims: Genetic variants that affect estrogen activity may influence the risk of Alzheimer's disease (AD). We examined the relation of polymorphisms in the gene for the estrogen receptor-beta (ESR2) to the risk of AD in women with Down syndrome. Methods: Two hundred and forty-nine women with Down syndrome, 31-70 years of age and nondemented at baseline, were followed at 14- to 18-month intervals for 4 years. Women were genotyped for 13 single-nucleotide polymorphisms (SNPs) in the ESR2 gene, and their association with AD incidence was examined. Results: Among postmenopausal women, we found a 2-fold increase in the risk of AD for women carrying 1 or 2 copies of the minor allele at 3 SNPs in introns seven (rs17766755) and six (rs4365213 and rs12435857) and 1 SNP in intron eight (rs4986938) of ESR2. Conclusion: These findings support a role for estrogen and its major brain receptors in modulating susceptibility to AD in women. © 2011 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Zhao, Q., Lee, J. H., Pang, D., Temkin, A., Park, N., Janicki, S. C., … Schupf, N. (2012). Estrogen receptor-beta variants are associated with increased risk of Alzheimer’s disease in women with Down syndrome. Dementia and Geriatric Cognitive Disorders, 32(4), 241–249. https://doi.org/10.1159/000334522

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free